Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 121 for:    severe preeclampsia AND delivery

First-trimester Prediction of Preeclampsia (PREDICTION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02189148
Recruitment Status : Completed
First Posted : July 14, 2014
Last Update Posted : July 23, 2019
Sponsor:
Collaborators:
Canadian Institutes of Health Research (CIHR)
Laval University
Information provided by (Responsible Party):
Emmanuel Bujold, CHU de Quebec-Universite Laval

Brief Summary:
Preeclampsia is a complication of pregnancy related to adverse maternal and neonatal outcomes, including fetal growth restriction and perinatal death. Several measures are used or under investigation (low-dose aspirin, low-molecular weight heparin, calcium, folic acid, among others) for the prevention of preeclampsia. Unfortunately, most high-risk women who could benefit from those preventive measures are not identified until late in pregnancy. Recent evidences suggest that the investigators could identify women at risk of developing preeclampsia using a combination of serum and ultrasound biomarkers in the first-trimester of pregnancy. This screening test needs external validation. A first-trimester screening strategy will strengthen clinical research on preeclampsia and will contribute to the development of strategy combining the prediction and prevention of the disease and its related complications.

Condition or disease
Preeclampsia Severe Preeclampsia Fetal Growth Restriction Preterm Birth

Detailed Description:

Background: Preeclampsia (PE) is a placenta-mediated pregnancy complication related to adverse maternal and neonatal outcomes, including intra-uterine growth restriction (IUGR) and perinatal death. A growing body of evidence suggests that the preterm and severe forms of PE are associated with deep placentation disorders that occur early in gestation. Over the last decade, maternal characteristic and first-trimester biomarkers, including some that are already used for aneuploidy screening (PAPP-A) have been strongly related to the preterm and early forms of PE, suggesting that early prediction is possible. Preventive measures are actually recommended (low-dose aspirin; calcium) or under investigation (folic acid; low-molecular weight heparin; anti-oxidant) in high-risk women. However, only women with chronic disease or prior adverse pregnancy outcomes are eligible for these measures while most cases of PE occur in nulliparous women. Moreover, there are actually no clear guidelines for clinicians in Canada whose pregnant patients have one or several risk factors for preeclampsia (obesity, chronic hypertension, low PAPP-A, etc.). On the other hand, it has been suggested that prediction of PE, and particularly the most severe cases, is possible with high sensitivity and specificity by using a combination of anamnestic, biophysical, biochemical and ultrasonographic biomarkers using the web-based Fetal-Medicine Foundation (FMF) screening test. This suggests that a strategy of prediction and prevention of PE and other placenta-mediated complications is becoming possible for nulliparous women as well. However, certain major concerns must be addressed: 1) The FMF screening test has not been validated prospectively; 2) a controversy exists about the need and feasibility of Doppler ultrasound in the general population.

Objectives:

  1. To validate the 11-13 week FMF screening test for early-onset PE and a composite of placenta-mediated outcomes (preterm PE, IUGR <3rd percentile, stillbirth); and
  2. To compare the screening test with and without uterine artery (UtA) Doppler;
  3. To explore the efficiency of new potential biomarkers (ADAM-12; Placental protein (PP) -13; placental and subplacental volume; placental vascularization) for prediction of PE in our population.

Methods: A multicenter prospective observational study of nulliparous women recruited between 11 3/7 - 13 6/7 weeks (maternal characteristics; BMI; Mean arterial pressure (MAP); PAPP-A; placental growth factor (PIGF); UtA Doppler…) and followed until delivery. Delivery and neonatal data will be collected through chart reviews. Detection rates for early-onset PE (primary outcome) and other adverse pregnancy outcomes will be measured using the 11-13 weeks FMF screening test with and without UtA Doppler results. A case-cohort study will be performed using stored serum samples and three-dimensional ultrasound volume acquired at the 11-13 weeks visit.

Feasibility and power calculation: We estimate a minimum incidence of early-onset PE of 0.7%. A minimum of 7,600 women will be necessary to demonstrate that the FMF screening test is at least 80% sensitive and 90% specific where it is expected that it will be 95% sensitive and 92% specific. We will have the power to detect an absolute difference of 15% in the detection rate between the different screening strategies (± Doppler). Recruitment will take 3.0 years. The overall study will take 5.0 years.

Expectations: First, our research will potentially provide a validated, highly sensitive and specific, and cheap tool to help clinicians' decision in the care of nulliparous women with risk factors for PE. In case of negative results, the clinician will have good evidence to reassure the patients facing abnormal maternal serum screening values. The validation of a first-trimester screening strategy will strengthen clinical research on PE providing new information on the natural evolution of the disease. Finally, this study will contribute to develop the optimal design for randomized trials aiming at the prevention of early-onset PE and other placenta-mediated complications of pregnancy.


Layout table for study information
Study Type : Observational
Actual Enrollment : 7554 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: First-trimester Prediction of Preeclampsia and Other Placenta-mediated Pregnancy Complications
Study Start Date : November 2014
Actual Primary Completion Date : December 2017
Actual Study Completion Date : March 2018

Resource links provided by the National Library of Medicine


Group/Cohort
Cohort

Each participant will :

  • give consent
  • provide a blood sample (10 ml)
  • be measured (weight and height for BMI calculation)
  • undergo a blood pressure measurement
  • have an ultrasound exam (uterine arteries Doppler, placental volume, thickness of the placenta)
  • answer to a short questionnaire (5 pages)



Primary Outcome Measures :
  1. early onset preeclampsia [ Time Frame: diagnosed between 20 and 34 weeks of gestation ]
    Preeclampsia will be defined according to the Canadian Guidelines for Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy guidelines, as de novo hypertension with diastolic blood pressure >90 mmHg on two occasions at least four hours apart, after 20 weeks of pregnancy, associated with proteinuria ≥300 mg/24 h or at least '2 +' protein on urine dipstick or an adverse conditions


Secondary Outcome Measures :
  1. Severe preeclampsia [ Time Frame: between 20 and 42 weeks of gestation ]
    Severe Preeclampsia will be defined by the presence of at least one of the following adverse condition: 1) systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 110 mmHg after 4 h of bed rest, 2) proteinuria ≥ 5 g/24 h or at least '3 +' protein on urine dipstick, or 3) oliguria < 400 ml/24 h; 4) cerebral or visual disturbances; epigastric pain; pulmonary edema or cyanosis; thrombocytopenia <100,000mm

  2. Fetal growth restriction [ Time Frame: between 20 and 42 weeks of gestation ]
    Fetal growth restriction will be defined as a birth weight below the 10th centile (or below the 3rd centile for severe FGR) of Canadian reference growth charts.


Biospecimen Retention:   Samples Without DNA
Maternal serum


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Nulliparous women who will deliver in one of the participating center:

CHUL Hospital, Quebec city, QC Hôpital Saint-François-d'Assise, Quebec city, QC CHU Ste-Justine, Montreal, QC Southern Alberta Maternal Fetal Medicine Centre, Calgary, Alberta Sinai Health System, Mount Sinai Hospital, Toronto, Ontario

Criteria

Inclusion Criteria:

  • gestational age between 11 3/7 and 13 6/7 weeks;
  • nulliparous women (no previous delivery ≥ 20 weeks).

Exclusion Criteria:

  • pregnant women <18 years old at recruitment;
  • multiple pregnancies;
  • fetal congenital malformation;
  • positive for HIV or hepatitis C or hepatitis B;
  • negative fetal heart at recruitment;
  • women planning a delivery outside the participating hospitals;
  • women not able to provide an informed consent to the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02189148


Locations
Layout table for location information
Canada, Alberta
South Alberta Maternal Fetal Medicine Centre, University of Calgary
Calgary, Alberta, Canada
Canada, Ontario
Sinai Health System, Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
Canada, Quebec
CHU Ste-Justine
Montreal, Quebec, Canada, H3T 1C5
CHU de Québec
Quebec city, Quebec, Canada, G1V 4G2
Sponsors and Collaborators
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR)
Laval University
Investigators
Layout table for investigator information
Principal Investigator: Emmanuel Bujold, MD, MSc CHU de Québec
Principal Investigator: François Audibert, MD, MSc St. Justine's Hospital

Additional Information:
Layout table for additonal information
Responsible Party: Emmanuel Bujold, Principal Investigator, CHU de Quebec-Universite Laval
ClinicalTrials.gov Identifier: NCT02189148     History of Changes
Other Study ID Numbers: CIHR-MOP-133672
B14-05-2024 ( Other Identifier: CER-CHU de Quebec )
First Posted: July 14, 2014    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Emmanuel Bujold, CHU de Quebec-Universite Laval:
Preeclampsia
Preterm birth
Prediction
Pregnancy
Placenta
Intra-uterine growth restriction
fetal growth restriction
Ultrasound
Doppler
Biomarkers
PAPP-A
Placental growth factor (PlGF)
Additional relevant MeSH terms:
Layout table for MeSH terms
Premature Birth
Pre-Eclampsia
Fetal Growth Retardation
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Hypertension, Pregnancy-Induced
Fetal Diseases
Growth Disorders
Pathologic Processes